Kemp H Kernstine1, James Moon2, Michael J Kraut3, Katherine M W Pisters4, Joshua R Sonett5, Valerie W Rusch6, Charles R Thomas7, Thomas K Waddell8, James R Jett9, Alan P Lyss10, Steven M Keller11, David R Gandara12. 1. Division of Thoracic Surgery, Department of Cardiovascular and Thoracic Surgery, Simmons Comprehensive Cancer Center, University of Texas Southwestern School of Medicine, Dallas, Texas. Electronic address: kemp.kernstine@utsouthwestern.edu. 2. Southwest Oncology Group Statistical Center, Seattle, Washington. 3. Providence Cancer Institute, Southfield, Michigan. 4. MD Anderson Cancer Center, Houston, Texas. 5. Columbia Presbyterian Medical Center, New York, New York. 6. Memorial Sloan-Kettering Cancer Center, New York, New York. 7. Department of Radiation Medicine, Knight Cancer Institute, Oregon Health Sciences University, Portland, Oregon. 8. University Health Network/The Toronto General Hospital, Toronto, Ontario, Canada. 9. Mayo Clinic, Rochester, Minnesota. 10. Heartland Cancer Research Community Clinical Oncology Program/Missouri Baptist Medical Center, St. Louis, Missouri. 11. Montefiore-Einstein Medical Center, Bronx, New York. 12. University of California Davis Cancer Center, Sacramento, California.
Abstract
BACKGROUND: Although preoperative chemotherapy (cisplatin-etoposide) and radiotherapy, followed by surgical resection, is considered a standard of care for superior sulcus cancers, treatment is rigorous and relapse limits long-term survival. The Southwest Oncology Group-Intergroup Trial S0220 was designed to incorporate an active systemic agent, docetaxel, as consolidation therapy. METHODS: Patients with histologically proven and radiologically defined T3 to 4, N0 to 1, M0 superior sulcus non-small cell lung cancer underwent induction therapy with cisplatin-etoposide, concurrently with thoracic radiotherapy at 45 Gy. Nonprogressing patients underwent surgical resection within 7 weeks. Consolidation consisted of docetaxel every 3 weeks for 3 doses. The accrual goal was 45 eligible patients. The primary objective was feasibility. RESULTS: Of 46 patients registered, 44 were eligible and assessable; 38 (86%) completed induction, 29 (66%) underwent surgical resection, and 20 (45% of eligible, 69% surgical, and 91% of those initiating consolidation therapy) completed consolidation docetaxel; 28 of 29 (97%) underwent a complete (R0) resection; 2 (7%) died of adult respiratory distress syndrome. In resected patients, 21 of 29 (72%) had a pathologic complete or nearly complete response. The known site of first recurrence was local in 2, local-systemic in 1, and systemic in 10, with 7 in the brain only. The 3-year progression-free survival was 56%, and 3-year overall survival was 61%. CONCLUSIONS: Although trimodality therapy provides excellent R0 and local control, only 66% of patients underwent surgical resection and only 45% completed the treatment regimen. Even in this subset, distant recurrence continues to be a major problem, particularly brain-only relapse. Future strategies to improve treatment outcomes in this patient population must increase the effectiveness of systemic therapy and reduce the incidence of brain-only metastases.
BACKGROUND: Although preoperative chemotherapy (cisplatin-etoposide) and radiotherapy, followed by surgical resection, is considered a standard of care for superior sulcus cancers, treatment is rigorous and relapse limits long-term survival. The Southwest Oncology Group-Intergroup Trial S0220 was designed to incorporate an active systemic agent, docetaxel, as consolidation therapy. METHODS:Patients with histologically proven and radiologically defined T3 to 4, N0 to 1, M0 superior sulcus non-small cell lung cancer underwent induction therapy with cisplatin-etoposide, concurrently with thoracic radiotherapy at 45 Gy. Nonprogressing patients underwent surgical resection within 7 weeks. Consolidation consisted of docetaxel every 3 weeks for 3 doses. The accrual goal was 45 eligible patients. The primary objective was feasibility. RESULTS: Of 46 patients registered, 44 were eligible and assessable; 38 (86%) completed induction, 29 (66%) underwent surgical resection, and 20 (45% of eligible, 69% surgical, and 91% of those initiating consolidation therapy) completed consolidation docetaxel; 28 of 29 (97%) underwent a complete (R0) resection; 2 (7%) died of adult respiratory distress syndrome. In resected patients, 21 of 29 (72%) had a pathologic complete or nearly complete response. The known site of first recurrence was local in 2, local-systemic in 1, and systemic in 10, with 7 in the brain only. The 3-year progression-free survival was 56%, and 3-year overall survival was 61%. CONCLUSIONS: Although trimodality therapy provides excellent R0 and local control, only 66% of patients underwent surgical resection and only 45% completed the treatment regimen. Even in this subset, distant recurrence continues to be a major problem, particularly brain-only relapse. Future strategies to improve treatment outcomes in this patient population must increase the effectiveness of systemic therapy and reduce the incidence of brain-only metastases.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: A Marra; W Eberhardt; C Pöttgen; D Theegarten; S Korfee; T Gauler; M Stuschke; G Stamatis Journal: Eur Respir J Date: 2006-09-13 Impact factor: 16.671
Authors: V W Rusch; D J Giroux; M J Kraut; J Crowley; M Hazuka; D Johnson; M Goldberg; F Detterbeck; F Shepherd; R Burkes; T Winton; C Deschamps; R Livingston; D Gandara Journal: J Thorac Cardiovasc Surg Date: 2001-03 Impact factor: 5.209
Authors: Laurie E Gaspar; Kari Chansky; Kathy S Albain; Eric Vallieres; Valerie Rusch; John J Crowley; Robert B Livingston; David R Gandara Journal: J Clin Oncol Date: 2005-05-01 Impact factor: 44.544
Authors: David R Gandara; Kari Chansky; Kathy S Albain; Bryan R Leigh; Laurie E Gaspar; Primo N Lara; Howard Burris; Paul Gumerlock; J Philip Kuebler; James D Bearden; John Crowley; Robert Livingston Journal: J Clin Oncol Date: 2003-05-15 Impact factor: 44.544
Authors: Hesham Elhalawani; Baher Elgohari; Timothy A Lin; Abdallah S R Mohamed; Thomas J Fitzgerald; Fran Laurie; Kenneth Ulin; Jayashree Kalpathy-Cramer; Thomas Guerrero; Emma B Holliday; Gregory Russo; Abhilasha Patel; William Jones; Gary V Walker; Musaddiq Awan; Mehee Choi; Roi Dagan; Omar Mahmoud; Anna Shapiro; Feng-Ming Spring Kong; Daniel Gomez; Jing Zeng; Roy Decker; Femke O B Spoelstra; Laurie E Gaspar; Lisa A Kachnic; Charles R Thomas; Paul Okunieff; Clifton D Fuller Journal: Clin Transl Radiat Oncol Date: 2019-01-06
Authors: Chris Dickhoff; Suresh Senan; Famke L Schneiders; Joris Veltman; Sayed Hashemi; Johannes M A Daniels; Marieke Fransen; David J Heineman; Teodora Radonic; Peter M van de Ven; Imke H Bartelink; Lilian J Meijboom; Juan J Garcia-Vallejo; Daniela E Oprea-Lager; Tanja D de Gruijl; Idris Bahce Journal: BMC Cancer Date: 2020-08-14 Impact factor: 4.430